Inotuzumab ozogamicin (CMC-544) is an antibody-drug conjugate for the treatment of cancers. It consists of the humanized monoclonal antibody inotuzumab (for CD22), linked to a cytotoxic agent from the class of calicheamicins (which is reflected by 'ozogamicin' in the drug's name).
This drug is being developed by Pfizer and UCB.
It has undergone numerous clinical trials, including two phase II trials for Non-Hodgkin lymphoma (NHL). 
A Phase III trial in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who were not candidates for intensive high-dose chemotherapy was terminated for futility.
As of April 2016Acute Lymphoblastic Leukemia (ALL)), six still recruiting.
ten clinical trials were active (including one phase III for
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Inotuzumab ozogamicin, American Medical Association.
- ^ Takeshita, A; Shinjo, K; Yamakage, N; Ono, T; Hirano, I; Matsui, H; Shigeno, K; Nakamura, S; Tobita, T; Maekawa, M (2009). "CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.". British journal of haematology. 146 (1): 34–43. doi:10.1111/j.1365-2141.2009.07701.x. PMID 19388933.
- ^ a b http://clinicaltrials.gov/ct2/results?term=Inotuzumab+ozogamicin
- ^ Pfizer Discontinues Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility. May 2013
- ^ An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)